Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Spitz

Showing results (321-330 of 323) with videos related to

Pageof 33
Sort By:
You have reached the last page of results.This site can display upto 323 results.
Gynecologic Oncology|September 29, 2016
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancerJonathan Oh, Minal Barve, Carolyn M Matthews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2021
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II StudyKathleen N Moore, Setsuko K Chambers, Erika P Hamilton, et al.
Gynecologic Oncology|June 4, 2024
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO studyVicky Makker, Jose Alejandro Perez-Fidalgo, Giorgio Valabrega, et al.
Pageof 33

Showing results (321-330 of 323) with videos related to

Sort By:
Pageof 33
You have reached the last page of results.This site can display upto 323 results.
Gynecologic Oncology|September 29, 2016
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancerJonathan Oh, Minal Barve, Carolyn M Matthews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2021
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II StudyKathleen N Moore, Setsuko K Chambers, Erika P Hamilton, et al.
Gynecologic Oncology|June 4, 2024
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO studyVicky Makker, Jose Alejandro Perez-Fidalgo, Giorgio Valabrega, et al.
Pageof 33